Tag: crizanlizumab

Clinical Trial Led by UTHSC’s Kenneth Ataga, MD, Results in FDA Approval of New Sickle Cell Treatment


Patients with sickle cell disease will soon have a new treatment option to reduce pain crises caused by obstructed blood flow. The FDA has approved use of the drug crizanlizumab based on the results of a clinical trial led by Kenneth Ataga, MD, Plough Foundation Endowed Chair in Sickle Cell Disease and director of the… Read More